

Artemisinin and Derivatives Cancer Studies

Breast Cancer

- (1) Bachmeier B *et al.* Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. *PLoS One*. 2011;6(5):e20550
- (2) Beekman AC *et al.* Stability of artemisinin in aqueous environments: impact on its cytotoxic action to Ehrlich ascites tumour cells. *J Pharm Pharmacol* 49:1254-1258, 1997.
- (3) Hamacher-Brady A *et al.* Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalysed lysosomal reactive oxygen species production. *J Biol Chem*. 2010 Dec 13
- (4) Fan Y *et al.* Effects of artesunate on anoikis resistance in human breast cancer cell MCF-7. *Zhongguo Bingli Shengli Zazhi* 22, 748-751, 2006.
- (5) Farsam V *et al.* Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. *Int Immunopharmacol*. 2011 Nov;11(11):1802-8
- (6) Lai H *et al.* Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. *Anticancer Res*. 2009 Oct;29(10):3807-10.
- (7) Lai H *et al.* Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. *Expert Opin Ther Targets*. 2005 Oct; 9(5):995-1007.
- (8) Lai H, Singh NP. Oral artemisinin prevents and delays the development of 7, 12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer in the rat. *Cancer Letters*. 2006 Jan 8; 231(1):43-8.
- (9) Langroudi L *et al.* A comparison of low-dose cyclophosphamide treatment with artemisinin treatment in reducing the number of regulatory T cells in murine breast cancer model. *Int Immunopharmacol*. 2010 Sep;10(9):1055-61.
- (10) Nakase H *et al.* Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. *Int. J. Pharmaceutics*. 2007.
- (11) Noori S *et al.* Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. *Int Immunopharmacol*. 2009 Nov 6.
- (12) Singh NP *et al.* Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo. *Anticancer Res*. 2011 Dec;31(12):4111-4.

- (13) Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin on human breast cancer cells. *Life Sciences* 70:49-56, 2001.
- (14) Sundar SN *et al.* Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen induced proliferation in human breast cancer cells. *Carcinogenesis*. 2008 Sep 10.
- (15) Tin AS *et al.* Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. *Anticancer Drugs*. 2012 Apr;23(4):370-9
- (16) Woerdenbag HJ *et al.* Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. *J Nat Prod* 56:849-856, 1993.
- (17) Zheng GQ. Cytotoxic terpenoids and flavonoids from *Artemisia annua*. *Planta Med* 60:54-57, 1994.